Rethinking Myasthenia Gravis: A global perspective on ABN's latest guidelines

In this special international episode, we explore the 2025 update of the Association of British Neurologists’ guidelines on managing autoimmune myasthenia gravis. Ten years after the previous recommendations, significant changes have been introduced. We emphasise the importance of daily steroids, early thymectomy, rituximab, and emerging targeted therapies transforming patient care. We also examine how these updates influence frontline care in the UK, Australia, and the USA, and why a multidisciplinary approach remains vital in the management of MG. Participants: Professor Alasdair Coles is Head of Department for Clinical Neuroscience and also Co-Director of the Cambridge Centre for Myelin Repair, UK. Associate Professor Katherine Buzzard, Clinical Lead, Eastern Health Multiple Sclerosis and Neuroimmunology Service, Melbourne, Australia. Dr. Christopher Doughty, MD is a board-certified neurologist, and affiliated with Brigham and Women's Hospital, in Boston, Massachusetts, USA. Read the paper ( ), which is part of the October issue of the Practical Neurology journal. Please

You can listen to Rethinking Myasthenia Gravis: A global perspective on ABN's latest guidelines online on Radio and Podcast. Open the player on this page to stream the available audio.

Rethinking Myasthenia Gravis: A global perspective on ABN's latest guidelines is an episode from PN podcast by BMJ Group.

This episode is 45:35 long.

This episode was published on Oct 7, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from PN podcast when more episodes are available from the podcast feed.